SBI Pharma (India) Manager Performance Evaluation

F0GBR06R8K -- India Fund  

INR 118.03  7.14  5.70%

The entity has beta of -0.1392 which indicates as returns on market increase, returns on owning SBI Pharma are expected to decrease at a much smaller rate. During bear market, SBI Pharma is likely to outperform the market.. Although it is extremely important to respect SBI Pharma Reg current price movements, it is better to be realistic regarding the information on equity historical returns. The way of measuring future performance of any fund is to evaluate the business as a whole together with its past performance including all available fundamental and technical indicators. By analyzing SBI Pharma Reg technical indicators you can today evaluate if the expected return of 0.0% will be sustainable into the future.
Horizon     30 Days    Login   to change

SBI Pharma Reg Relative Risk vs. Return Landscape

If you would invest  11,803  in SBI Pharma Reg Gr on October 16, 2018 and sell it today you would earn a total of  0.00  from holding SBI Pharma Reg Gr or generate 0.0% return on investment over 30 days. SBI Pharma Reg Gr is generating negative expected returns and assumes 0.0% volatility on return distribution over the 30 days horizon. Simply put, 0% of equities are less volatile than SBI Pharma Reg Gr and 99% of equity instruments are likely to generate higher returns than the company over the next 30 trading days.
 Daily Expected Return (%) 
      Risk (%) 

SBI Pharma Current Valuation

Not valued
November 15, 2018
118.03
Market Value
0.00
Real Value
Target Odds
  
0.00
Upside
SBI Pharma is Unknown risk asset. SBI Pharma Reg current Real Value cannot be determined due to lack of data. The regular price of SBI Pharma Reg is 118.03. Based on Macroaxis valuation methodology, the entity cannot be evaluated at this time. We determine the value of SBI Pharma Reg from analyzing fund fundamentals and technical indicators as well as its Probability Of Bankruptcy. In general, we recommend to buy undervalued stocks and to dispose of overvalued stocks since in the future securities prices and their ongoing real values will draw towards each other.

SBI Pharma Market Risk Analysis

Sharpe Ratio = 0.0
Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small Returns
CashSmall
Risk
Average
Risk
High
Risk
Huge
Risk
F0GBR06R8K
Based on monthly moving average SBI Pharma is performing at about 0% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of SBI Pharma by adding it to a well-diversified portfolio.

SBI Pharma Performance Rating

SBI Pharma Reg Gr Risk Adjusted Performance Analysis

0 

Risk-Adjusted Fund Performance

Over the last 30 days SBI Pharma Reg Gr has generated negative risk-adjusted returns adding no value to fund investors.

SBI Pharma Alerts

Equity Alerts and Improvement Suggestions

SBI Pharma Reg is not yet fully synchronised with the market data
The fund retains about 5.48% of its assets under management (AUM) in cash

SBI Pharma Performance Indicators

SBI Pharma Reg Basic Price Performance Measures

Fifty Two Week Low120.0020
Fifty Two Week High128.0990
Annual Report Expense Ratio2.73%
Additionally see Investing Opportunities. Please also try Balance Of Power module to check stock momentum by analyzing balance of power indicator and other technical ratios.
Search macroaxis.com